IP Verse

Methods For Treating Intrapulmonary Infections - EP3616695

The patent EP3616695 was granted to Merck Sharp & Dohme on Oct 23, 2024. The application was originally filed on Sep 7, 2012 under application number EP19203616A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3616695

MERCK SHARP & DOHME
Application Number
EP19203616A
Filing Date
Sep 7, 2012
Status
Granted And Under Opposition
Sep 19, 2024
Grant Date
Oct 23, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ADALVOJul 23, 2025SLAVIKADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS7129232

Non-Patent Literature (NPL) Citations (31) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- LEVY, J. et al., "Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum", J Infect Dis, (19830000), vol. 148, no. 6, pages 1069 - 76, XP001106350
DESCRIPTION- PENNINGTON, J. E., "Penetration of antibiotics into respiratory secretions", Rev Infect Dis, (19810000), vol. 3, no. 1, pages 67 - 73
DESCRIPTION- TODA et al., "Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205", Bioorganic & Medicinal Chemistry, (20080000), vol. 18, doi:doi:10.1016/j.bmcl.2008.07.085, pages 4849 - 4852, XP024100115
DESCRIPTION- TODA et al., "Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205", Bioorganic & Medicinal Chemistry Letters, (20080000), vol. 18, doi:doi:10.1016/j.bmcl.2008.07.085, pages 4849 - 4852, XP024100115
EXAMINATION- Anonymous, "Cubist Pharmaceuticals Corporate Presentation", (20100201), URL: http://rationalinvesting.com/present/CBST.pdf, (20150306), XP055174525
EXAMINATION- Anonymous, "Cubist Pharmaceuticals to Acquire Calixa Therapeutics", (20091214), URL: http://investors.cubist.com/Mobile/file.aspx?IID=4093793&FID=8747721, (20150306), XP055174426
OPPOSITION- Anonymous, "Assessment report Zerbaxa : EMA/463294/2019 : Procedure No. EMEA/H/C/003772/II/0020 ", Assessment report Zerbaxa, European Medicines Agency, (20190725), pages 1 - 125, Assessment report Zerbaxa, URL: https://www.ema.europa.eu/en/documents/variation-report/zerbaxa-h-c-3772-ii-0020-epar-assessment-report-variation_en.pdf, XP093302076
OPPOSITION- Anonymous, "Cubist Pharmaceuticals Corporate Presentation ", (20100201), URL: http://rationalinvesting.com/present/CBST.pdf, (20150306), XP055174525
OPPOSITION- Anonymous, "Cubist Pharmaceuticals Corporate Presentation", (20110901), URL: http://www.snl.com/interactive/lookandfeel/4093793/Cubist.IP.09.06.pdf, (20150306), XP055174365
OPPOSITION- Anonymous, "Cubist Pharmaceuticals presentation: CXA-201 A novel cephalosporin/tazobactam combination product being developed for the treatment of infections due to drug-resistant Pseudomonas aeruginosa and other Gram-negative pathogens (Board of Director’s Meeting December 3, 2009 Commercial Presentation)", Investor Pipeline and R&D Event held at NASDAQ MarketSite on 09.20/10;, (20110206), pages 1 - 21, XP093302006
OPPOSITION- Chandorkar G, J Huntington, T Parsons, M Gotfried, O Umeh, "POSTER # P1627 PENETRATION OF CEFTOLOZANE/TAZOBACTAM AND PIPERACILLIN/TAZOBACTAM INTO THE EPITHELIAL LINING FLUID OF HEALTHY VOLUNTEERS", ECCMID 2012; 22nd European Congress of Clinical Microbiology and Infectious Diseases; March 31 - April 3, 2012, London, UK, ESCMID Society, (20120331), pages 1 - 1, XP093302035
OPPOSITION- D17 - Printout of a ChatGPT simulation of a skilled person in the field of antibiotics on the priority date of 07 June 2012; Accessed via https://chat.openai.com/
OPPOSITION- Marier J F; Trinh M M; Chang C; Ge Y; Benziger D, "Pharmacokinetics of a Novel Anti-Pseudomonal Cephalosporin, CXA-101, and Tazobactam (CXA/TAZ) in Healthy Adult Subjects", Abstracts Book, Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), American Society for Microbiology, US, US , (20100914), vol. 50, ISSN 0733-6373, pages A - 1391, XP055174470
OPPOSITION- Alan J. Xiao, Benjamin W. Miller, Jennifer A. Huntington, David P. Nicolau, "Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia", The Journal of clinical pharmacology, LIPPINCOTT CO, HAGERSTOWN, MD, US, US , (20160101), vol. 56, no. 1, doi:10.1002/jcph.566, ISSN 0091-2700, pages 56 - 66, XP055576838
OPPOSITION- Boselli Emmanuel; Breilh Dominique; Rimmelé Thomas; Poupelin Jean-Charles; Saux Marie-Claude; Chassard Dominique; Allaouchiche Bernard, "Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia", Intensive Care Medicine, Springer Berlin Heidelberg, Berlin/Heidelberg, Berlin/Heidelberg, (20040224), vol. 30, no. 5, doi:10.1007/s00134-004-2171-2, ISSN 0342-4642, pages 989 - 991, XP038160250
OPPOSITION- Roberts J. A., Kirkpatrick C. M. J., Lipman J., "Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients", Journal of antimicrobial chemotherapy, OXFORD UNIVERSITY PRESS, GB, GB , (20110201), vol. 66, no. 2, doi:10.1093/jac/dkq449, ISSN 0305-7453, pages 227 - 231, XP093302000
OPPOSITION- Roberts Jason A., Kruger Peter, Paterson David L., Lipman Jeffrey, "Antibiotic resistance—What’s dosing got to do with it?", Critical Care Medicine, Lippincott Williams & Wilkins, (20080801), vol. 36, no. 8, doi:10.1097/CCM.0b013e318180fe62, ISSN 0090-3493, pages 2433 - 2440, XP009562302
OPPOSITION- L. Zamorano, C. Juan, A. Fernández-Olmos, Y. Ge, R. Cantón, A. Oliver, "Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients", Clinical Microbiology and Infection, (20100901), vol. 16, no. 9, doi:10.1111/j.1469-0691.2010.03130.x, ISSN 1198743X, pages 1482 - 1487, XP055174517
OPPOSITION- H. S. Sader, Rhomberg P. R., Farrell D. J., Jones R. N., "Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes", Antimicrobial agents and chemotherapy, American Society for Microbiology., (20110501), vol. 55, no. 5, doi:10.1128/AAC.01737-10, ISSN 00664804, pages 2390 - 2394, XP055065385
OPPOSITION- Y. Ge, Whitehouse M. J., Friedland I., Talbot G. H., "Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, American Society for Microbiology, US, US , (20100801), vol. 54, no. 8, doi:10.1128/AAC.01753-09, ISSN 0066-4804, pages 3427 - 3431, XP055174519
OPPOSITION- B. Miller, E. Hershberger, D. Benziger, M. Trinh, I. Friedland, "Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses", Antimicrobial agents and chemotherapy, American Society for Microbiology., (20120601), vol. 56, no. 6, doi:10.1128/AAC.06349-11, ISSN 00664804, pages 3086 - 3091, XP055116077
OPPOSITION- Moriyama Brad, Henning Stacey A, Childs Richard, Holland Steven M, Anderson Victoria L, Morris John C, Wilson Wyndham H, Drusano George L, Walsh Thomas J, "High-Dose Continuous Infusion β-Lactam Antibiotics for the Treatment of Resistant Pseudomonas Aeruginosa Infections in Immunocompromised Patients", Annals of Pharmacotherapy, SAGE Publications, Los Angeles, CA, Los Angeles, CA, (20100501), vol. 44, no. 5, doi:10.1345/aph.1M717, ISSN 1060-0280, pages 929 - 935, XP093301998
SEARCH- Anonymous, "Cubist Pharmaceuticals Corporate Presentation", (20110906), URL: http://www.snl.com/interactive/lookandfeel/4093793/Cubist.IP.09.06.pdf, (20150306), XP055174365 [I] 1-9 * pages 38-40,44 * [Y] 1-9
SEARCH- JACQUELINE C; DESESSARD C; ROQUILLY A; LE MABECQUE V; BOUTOILLE D; GE J Y; ASEHNOUNE K; CAILLON J; POTEL G, "Assessment of the In Vivo Activity of CXA-101 in a Murine Model of Pseudomonas aeruginosaPneumonia: Comparison with Ceftazidime and Piperacillin-Tazobactam", ABSTRACTS BOOK, INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS & CHEMOTHERAPY (ICAAC), US, (20100914), vol. 50, ISSN 0733-6373, pages B - 1401, XP055174471 [I] 1-9 * abstract * [Y] 1-9
SEARCH- MARIER J F; TRINH M M; CHANG C; GE Y; BENZIGER D, "Pharmacokinetics of a Novel Anti-Pseudomonal Cephalosporin, CXA-101, and Tazobactam (CXA/TAZ) in Healthy Adult Subjects", ABSTRACTS BOOK, INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS & CHEMOTHERAPY (ICAAC), US, (20100914), vol. 50, ISSN 0733-6373, pages A - 1391, XP055174470 [Y] 1-9 * abstract *
SEARCH- ALAN J. XIAO ET AL, "Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia", JOURNAL OF CLINICAL PHARMACOLOGY., US, (20150825), vol. 56, no. 1, doi:10.1002/jcph.566, ISSN 0091-2700, pages 56 - 66, XP055576838 [T] * the whole document *
SEARCH- L. ZAMORANO ET AL, "Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients", CLINICAL MICROBIOLOGY AND INFECTION, (20091207), vol. 16, no. 9, doi:10.1111/j.1469-0691.2010.03130.x, ISSN 1198-743X, pages 1482 - 1487, XP055174517 [I] 1-9 * abstract * [Y] 1-9
SEARCH- H. S. SADER ET AL, "Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20110214), vol. 55, no. 5, doi:10.1128/AAC.01737-10, ISSN 0066-4804, pages 2390 - 2394, XP055065385 [I] 1-9 * abstract * [Y] 1-9
SEARCH- Y. GE ET AL, "Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20100510), vol. 54, no. 8, doi:10.1128/AAC.01753-09, ISSN 0066-4804, pages 3427 - 3431, XP055174519 [Y] 1-9 * abstract * * tables 4,5 *
SEARCH- B. MILLER ET AL, "Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20120326), vol. 56, no. 6, doi:10.1128/AAC.06349-11, ISSN 0066-4804, pages 3086 - 3091, XP055116077 [YP] 1-9 * abstract * * tables 2,3 *
SEARCH- GIANPAOLO PERLETTI ET AL, "CXA-101", DRUGS OF THE FUTURE, (201012), vol. 35, no. 12, doi:10.1358/dof.2010.35.12.1541551, ISSN 0377-8282, pages 977 - 986, XP055174370 [A] 1-9 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents